Next Article in Journal
Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991–2012: A Retrospective, Longitudinal Study
Next Article in Special Issue
From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials
Previous Article in Journal / Special Issue
Techniques for Screening Translation Inhibitors
Article Menu

Export Article

Open AccessReview
Antibiotics 2016, 5(3), 24;

Ribosomal Antibiotics: Contemporary Challenges

Department of Structural Biology, Weizmann Institute, Rehovot 76100, Israel
Author to whom correspondence should be addressed.
Academic Editor: Claudio O. Gualerzi
Received: 13 April 2016 / Revised: 7 June 2016 / Accepted: 20 June 2016 / Published: 29 June 2016
(This article belongs to the Special Issue Inhibitors of the Translational Apparatus)
PDF [4591 KB, uploaded 29 June 2016]


Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of “pathogen-specific antibiotics,” in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification. View Full-Text
Keywords: multi-drug resistance; microbiome; species-specific antibiotics susceptibility; novel degradable antibiotics multi-drug resistance; microbiome; species-specific antibiotics susceptibility; novel degradable antibiotics

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Auerbach-Nevo, T.; Baram, D.; Bashan, A.; Belousoff, M.; Breiner, E.; Davidovich, C.; Cimicata, G.; Eyal, Z.; Halfon, Y.; Krupkin, M.; Matzov, D.; Metz, M.; Rufayda, M.; Peretz, M.; Pick, O.; Pyetan, E.; Rozenberg, H.; Shalev-Benami, M.; Wekselman, I.; Zarivach, R.; Zimmerman, E.; Assis, N.; Bloch, J.; Israeli, H.; Kalaora, R.; Lim, L.; Sade-Falk, O.; Shapira, T.; Taha-Salaime, L.; Tang, H.; Yonath, A. Ribosomal Antibiotics: Contemporary Challenges. Antibiotics 2016, 5, 24.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top